Media Coverage

Cancer molecular diagnostics company Biofidelity this week presented the results of three studies the American Association for Cancer Research (AACR) annual meeting showcasing the consistency, reproducibility, and superiority in certain sample types with Aspyre Lung.

Biofidelity’s successful $24 million financing round, which brings the total funding raised to $60m since being founded in 2019, will accelerate the growth of its game-changing Aspyre Lung genomic testing protocol.

Biofidelity, a genomic technology company with headquarters in the Research Triangle Park, has raised $24 million from investors in a new round of funding.

Biofidelity has completed a $24 million funding round, bringing the company's total financing to $60 million since it was founded in 2019. The company develops technology to support precision medicine.

Biofidelity, a Cambridge-based genomic technology company at the commercial stage, has announced a significant funding boost of $24M (approximately €22M), bringing its total funding to $60M (approximately €55.3M).

Genomic tech company Biofidelity, which has operations in Cambridge and North Carolina commercialising precision medicine for patients worldwide, has raised $24 million growth capital.

In this episode, host Shikha Jain, MD speaks with Barnaby Balmforth, PhD about the evolution of genomics in cancer care, the impact of personalized care tools, and more.

Biofidelity addresses genome sequencing challenges by using a targeted approach and unique technology that allows for local testing using PCR rather than DNA sequencers.

Biofidelity, a genomic technology company with UK headquarters at Cambridge Science Park and a US flagship in North Carolina, is enabling laboratories worldwide to perform rapid precision genomic analysis through the launch of its Aspyre Lung Reagents.

Genomic technology company Biofidelity has announced the launch of Aspyre Lung Reagents for research use, marking its second product launch this year, with the aim of providing simpler, faster analysis of comprehensive genomic biomarkers to existing solutions.

Barnaby Balmforth, CEO of Biofidelity receives the Life Science Innovation Award from AstraZeneca’s Shaun Grady and Sir Greg Winter.

Biofidelity, a British genomic technology company with U.S. headquarters in Morrisville, has commercially launched a novel assay to guide the treatment of non-small cell lung cancer in U.S. patients.

Lung cancer is the leading cause of cancer deaths in the US, with more than 200,000 cases diagnosed every year, according to a Biofidelity press release from Tuesday.

Biofidelity’s Wendy Levin MD, MS, Chief Medical Officer, and Todd Kelley MD, Executive Director of Medical Affairs, were interviewed by OncologyTube.com about our recent publication in BMC Genomics.

Biofidelity, a Cambridge and US pioneer in precision cancer diagnostics, has completed a significantly oversubscribed $23 million Series A+ round, led by Octopus Ventures and backed by SBI Investment Co. Ltd. and existing investors.

Cambridge Science Park company Biofidelity expects to launch Aspyre Lung, its first commercial diagnostic assay in the US in early 2022.

Over the past two decades, DNA sequencing has transformed our understanding of cancer. Knowledge of the genetic pathways that drive disease enabled the development of new therapies that directly target specific genetic mutations.

Deals valued at over £1 million in the East of England life science cluster in the last 12 calendar months totalled $50.371 billion – and that doesn’t include current and potential milestone payments, some of which are huge.

Looking at a last 12 months of significant transactions, cash has been flying into the Cambridge cluster from where news of bleeding edge technology positively flies across the Atlantic.

The global economic and societal challenges brought by COVID-19 have impacted all industries, many quite extensively, writes Simon Ormiston, partner at PwC in Cambridge.

Cambridge UK startup Biofidelity Ltd, a cancer diagnostics company, has completed a $12 million Series A financing to fast-track its technology to a $15 billion global market.

Cambridge startup Biofidelity Ltd, which is providing advanced molecular assays for the sensitive detection of low-frequency genetic mutations, has won £500,000 in grant funding from Innovate UK.